当前位置:首页 >财报库 > 报告详情

雅培Abbott Laboratories(ABT)2025年年度报告「NYSE」(英文版)(86页).pdf

上传人: 1****1 编号:1193154 2026-04-17 86页 11.18MB

1、2025 Annual Report1 Letter to shareholders5 Durable by design6 Building on breadth8 Creating the future10 Driven by people12 Biowearables14 Neuromodulation16 Cardiac Rhythm Management18 Electrophysiology20 Structural Heart22 Vascular24 Heart Failure Management26 Medicines28 Laboratory Diagnostics30

2、Rapid and Molecular Diagnostics32 Nutrition34 Making a difference36 Financial Report2025 Annual ReportWhen Stran,a rancher and rodeo world champion,had a stroke at 32 caused by a patent foramen ovale(PFO)an opening between the right and left sides of the upper chambers of the heart he received an Am

3、platzer PFO occluder.Today,hes back in the saddle and working his ranch with his family.Front Cover:STRAN SMITHChildress,Texas,USAAmplatzer PFO occluderDear fellow shareholder,Dear fellow shareholder,In a year of rapid,constant,and volatile In a year of rapid,constant,and volatile change,Abbott agai

4、n demonstrated what change,Abbott again demonstrated what has set it apart and kept it thriving for has set it apart and kept it thriving for 138 years:vision,know-how,adaptability,138 years:vision,know-how,adaptability,and the determination that comes from and the determination that comes from a co

5、mpelling sense of purpose.a compelling sense of purpose.Robert Ford Chairman of the Board and Chief Executive Officer$5.15Adjusted diluted EPS reflects double-digit growth*6.7%Organic sales growth underlying base business*$44.3BWorldwide sales 2025:Strong performance across key financial measures2Ab

6、bott /2025 Annual ReportNavigating the environment2025 was a year that favored the long view looking to both the past and the future.Our deep experience has prepared us to deal with challenges and put them in perspective.And our established long-term orientation helps us look past the turbulence of

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
1. **财务表现**:2025年全球销售额443亿美元,有机增长6.7%;调整后每股收益5.15美元,增长10%;连续408个季度分红,54年持续增长。 2. **创新与产品**:推出Volt脉冲场消融系统、Tendyne经导管二尖瓣置换系统等;超200项临床试验,包括TECTONIC和Veritas试验。 3. **业务拓展**:收购Exact Sciences(2025年收入超30亿美元),将诊断业务年收入提升至120亿美元;在墨西哥、乔治亚州扩建工厂。 4. **全球影响**:产品服务全球20亿人;捐赠3600万美元支持50国人道主义;血液计划挽救24万生命。 5. **核心战略**:多元化业务布局(生物可穿戴设备、神经调控、心血管等),强调长期韧性、创新与可及性。
**Abbott创新亮点?** **健康科技新突破?** **全球医疗影响力?**
客服
商务合作
小程序
服务号
折叠